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Fabry  disease  is  an  X-linked  lysosomal  storage  disor-
der (LSD) caused by mutations in the gene (GLA) that 
encodes  the  lysosomal  hydrolase  α-galactosidase  A 
(α-Gal A), and is characterized by pathological accumu-
lation  of  the  substrate,  globotriaosylceramide  (GL-3). 
Regular infusion of recombinant human α-Gal A (rhα-
Gal A), termed enzyme replacement therapy (ERT), is 
the primary treatment for Fabry disease. However, rhα-
Gal A has low physical stability, a short circulating half-
life, and variable uptake into different disease-relevant 
tissues. We hypothesized that coadministration of the 
orally available, small molecule pharmacological chap-
erone AT1001 (GR181413A, 1-deoxygalactonojirimycin, 
migalastat hydrochloride) may improve the pharmaco-
logical properties of rhα-Gal A via binding and stabili-
zation. AT1001 prevented rhα-Gal A denaturation and 
activity loss in vitro at neutral pH and 37 °C. Coincuba-
tion  of  Fabry  fibroblasts  with  rhα-Gal  A  and  AT1001 
resulted in up to fourfold higher cellular α-Gal A and 
~30% greater GL-3 reduction compared to rhα-Gal A 
alone. Furthermore, coadministration of AT1001 to rats 
increased the circulating half-life of rhα-Gal A by >2.5-
fold, and in GLA knockout mice resulted in up to fivefold 
higher α-Gal A levels and fourfold greater GL-3 reduction 
than rhα-Gal A alone. Collectively, these data highlight 
the potentially beneficial effects of AT1001 on rhα-Gal A, 
thus warranting clinical investigation.
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published online 3 January 2012. doi:10.1038/mt.2011.271
IntroductIon
Fabry disease (OMIM 301500) is an X-linked lysosomal storage 
disorder (LSD) caused by inherited mutations in the gene (GLA) 
that encodes α-galactosidase A (α-Gal A; EC 3.2.1.22).1,2 Deficiency 
of α-Gal A results in progressive accumulation and deposition of 
neutral  glycosphingolipids  with  terminal  α-galactosyl  residues, 
primarily globotriaosylceramide (GL-3, also known as Gb3 or 
CTH), in cells of the heart, kidney, skin, brain, eyes, and other tis-
sues, which is believed to contribute to the life-threatening mani-
festations of Fabry disease.1–3 The clinical presentation of Fabry 
disease spans a broad spectrum of severity and roughly correlates 
with residual α-Gal A activity.2,4
Enzyme replacement therapy (ERT) is currently the primary 
treatment  for  Fabry  disease.  ERT  is  based  on  the  intravenous 
administration of recombinant human α-Gal A (rhα-Gal A), of 
which Fabrazyme (agalsidase β; Genzyme, Cambridge, MA) and 
Replagal (agalsidase alfa; Shire Pharmaceuticals, Cambridge, MA) 
are the only two approved products. These therapies are gener-
ally well-tolerated, and in some patients reduce plasma, urine, and 
microvascular endothelial GL-3 levels,5,6 stabilize kidney function,7 
and alleviate neuropathic pain, reverse or improve hypertrophic 
cardiomyopathy, and increase the ability to sweat.6,8,9 However, 
the infused recombinant enzymes tend to be unstable at neutral 
pH, resulting in a short-circulating half-life of the properly folded 
active enzyme in vivo.5,10 Furthermore, delivery and uptake of ERT 
to some cells, tissues, and organs is insufficient in certain cases, 
as suggested by the inability of infused rhα-Gal A to significantly 
reduce GL-3 in cardiomyocytes, distal convoluted tubules, and 
glomerular podocytes, as well as the central nervous system.5,10 In 
addition, the infused enzymes can be immunogenic, which may 
limit efficacy11 and sometimes adversely affect tolerability.12,13
Small molecule pharmacological chaperones (PCs) have been 
proposed  as  a  potential  therapy  for  Fabry  disease.14  The  imino-
sugar, 1-deoxygalactonojirimycin (AT1001, GR181413A, migalastat 
hydrochloride) is an analog of the terminal galactose of GL-3 that 
selectively and reversibly binds and stabilizes wild type and mutant 
forms of α-Gal A,15,16 and when used alone as a monotherapy has 
been shown to reduce the storage of GL-3 in vitro and in vivo.17–20 In 
contrast to ERT, AT1001 is orally available and has broad tissue dis-
tribution, including access to the central nervous system.19 As such, 
AT1001 is currently in clinical development to evaluate its safety and 
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efficacy as a monotherapy for Fabry disease.21 PCs have also been 
identified that selectively bind and increase the levels of mutated 
enzymes associated with several other LSDs, including Gaucher, 
Tay-Sachs, Sandhoff, GM1-gangliosidosis, and Pompe disease.22
Recently, PCs have also shown positive effects on several exog-
enous recombinant enzymes that are used to treat LSDs, including 
increased physical stability and improved cellular and tissue uptake. 
Specifically, the PCs isofagomine and N-butyldeoxynojirimycin 
were shown to increase the in vitro cellular uptake and in vivo tis-
sue uptake of the recombinant enzymes used to treat Gaucher and 
Pompe diseases, respectively.23,24 Similarly, AT1001 was shown to 
increase the cellular uptake of rhα-Gal A in Fabry patient-derived 
cells in vitro.23
In the present study, we demonstrate that AT1001 stabilizes 
rhα-Gal A (agalsidase β) in vitro, minimizing protein denaturation 
and inactivation at neutral pH and physiological temperature. In 
addition, incubation of cultured cells derived from Fabry patients 
with AT1001 results in a concentration-dependent increase in the 
cellular uptake of rhα-Gal A. Studies in rats and GLA knockout 
(KO) mice indicate that AT1001 coadministration increases the 
circulating half-life of rhα-Gal A, resulting in significant and dose-
dependent increases in rhα-Gal A levels in disease-relevant tis-
sues. Most importantly, we show that AT1001-mediated increases 
in cellular and tissue levels of rhα-Gal A result in greater reduc-
tion of GL-3 compared to rhα-Gal A alone in patient-derived cells 
and tissues of GLA KO mice, indicating a “boost” in the net lyso-
somal activity from the exogenous recombinant enzyme. Taken 
together, these data indicate that AT1001 can increase the stabil-
ity and improve the pharmacokinetic properties of ERT, thereby 
leading to greater tissue levels and substrate reduction. As such, 
a therapeutic approach for Fabry disease that combines a small 
molecule PC with ERT may warrant clinical investigation.
results
At1001 stabilizes rhα-Gal A, preventing denaturation 
and loss of activity
The effect of AT1001 binding on the stability of rhα-Gal A was 
assessed using a fluorescence-based thermal denaturation assay.25 
At neutral pH, rhα-Gal A was significantly less stable [melting 
temperature (Tm) 47 °C] than at acidic pH (Tm 58 °C) (Figure 1a). 
Importantly, coincubation with AT1001 at neutral pH resulted 
in  a  concentration-dependent  stabilization  of  rhα-Gal  A,  with 
100 μmol/l  AT1001  shifting  the  Tm  to  58 °C,  similar  to  that 
observed for the enzyme alone at acidic pH (Figure 1a). A con-
centration-dependent stabilization of rhα-Gal A with AT1001 at 
acidic pH was also observed. The Tm for rhα-Gal A shifts from 
58 °C to 68 °C and 72 °C with 10 and 100 μmol/l AT1001, respec-
tively  (data  not  shown).  Furthermore,  incubation  at  neutral 
pH/37 °C resulted in time-dependent denaturation of rhα-Gal A, 
with a half-life of ~9 hours (Figure 1b). Incubation in the pres-
ence of AT1001 (10 μmol/l; Figure 1b), or in acidic buffer (data 
not shown), prevented rhα-Gal A denaturation for up to 24 hours. 
Additionally,  incubation  of  rhα-Gal  A  in  human  whole  blood 
resulted in a time-dependent loss of activity, with a half-life of ~2 
hours (Figure 1c). Again, coincubation with AT1001 (1 μmol/l) 
increased the half-life of rhα-Gal A in blood to ~8 hours. Taken 
together, these results demonstrate that AT1001 stabilizes rhα-Gal 
A, preventing pH-, time-, and temperature-dependent denatur-
ation and inactivation.
At1001/rhα-Gal A coincubation results in greater 
α-Gal A levels and enzyme activity in Fabry fibroblasts 
compared to incubation with rhα-Gal A alone
The effect of AT1001 coincubation on rhα-Gal A was assessed 
in  Fabry  patient-derived  fibroblast  cell  lines  that  show  rhα-
Gal  A-dependent  reduction  of  elevated  GL-3  (Supplementary 
Figure S1). In these cell lines, 5-hour incubation with rhα-Gal 
A (0.4 nmol/l–0.5 nmol/l) led to a partial (≤50% of maximum) 
increase in α-Gal A activity and decrease in GL-3 (Supplementary 
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Figure  1  At1001  increases  the  physical  stability  of  recombinant 
human α-Gal A (rhα-Gal A) in vitro. (a) Thermal stability scans of rhα-
Gal A in the absence and presence of various AT1001 concentrations. All 
experiments were performed at pH 7.4, with the exception of Apo (pH 
5.2; red). Unfolding of rhα-Gal A was monitored by changes in the fluo-
rescence of SYPRO Orange as a function of temperature. (b) Time course 
of rhα-Gal A unfolding in neutral buffer (pH 7.4) at 37 °C in the absence 
and presence of 10 μmol/l AT1001. Unfolding of rhα-Gal A was moni-
tored by changes in the fluorescence of SYPRO Orange as a function of 
time. (c) Time course of rhα-Gal A inactivation in human whole blood at 
37 °C in the absence and presence of 1 μmol/l AT1001. α-Galactosidase 
A (α-Gal A) enzyme activity was determined at the indicated time points 
using 4-methylumbelliferyl-α-d-galactopyranoside (4-MUG). To obtain 
relative enzyme activity levels, measurements at the various time points 
were compared to the activity at time zero.Molecular Therapy  vol. 20 no. 4 apr. 2012  719
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Figure S2a–c). In C52S Fabry fibroblasts that have no endog-
enous α-Gal A activity and show no increase in α-Gal A levels 
in response to AT1001 alone17, 5-hour coincubation with rhα-
Gal  A  (0.5 nmol/l)  and  increasing  concentrations  of  AT1001 
(10–1,000 μmol/l)  resulted  in  4.4–5.6-fold  more  cellular  α-Gal 
A protein 2 days later compared to rhα-Gal A incubation alone 
(Figure 2a and Table  1). As expected, 5-hour incubation with 
AT1001 alone (10–1,000 μmol/l) showed no increase in α-Gal A 
protein levels (Figure 2a) or activity (data not shown). However, 
after 5-hour rhα-Gal A and AT1001 coincubation, approximately 
threefold higher α-Gal A activity was seen 2 days later as com-
pared to rhα-Gal A incubation alone [Figure 2b (blue bars) and 
Table 1]. The concentration of rhα-Gal A that yielded 50% of the 
maximal effect (EC50 value) was reduced approximately tenfold 
following  AT1001  coincubation  compared  to  incubation  with 
rhα-Gal A alone [4.6 ± 1.3 nmol/l (n = 4) versus 48 ± 14 nmol/l 
(n = 4), respectively; P<0.05 by t-test; Figure 2c (blue lines)], 
indicating that the potency of rhα-Gal A uptake was greater when 
coincubated with AT1001. In Fabry fibroblasts that endogenously 
express AT1001-responsive mutant forms (R301Q and L300P),17 
rhα-Gal A and AT1001 coincubation similarly resulted in 3.0–
3.3-fold higher α-Gal A activity compared to rhα-Gal A alone 
(Table 1). Incubation with 1,000 μmol/l AT1001 alone minimally 
increased α-Gal A activity in these cells 2 days later [1.5 ± 0.3-
fold and 1.8 ± 0.1-fold above baseline levels in R301Q and L300P, 
respectively; n = 4 each], but the magnitudes of increase did not 
reach those seen with either rhα-Gal A incubation alone or with 
rhα-Gal A and AT1001 coincubation (Table 1).
At1001/rhα-Gal A coincubation leads to greater 
Gl-3 reduction in Fabry fibroblasts compared to 
incubation with rhα-Gal A alone
Coincubation  of  C52S  fibroblasts  with  rhα-Gal  A  (0.5 nmol/l) 
and AT1001 (1,000 μmol/l) for 5 hours resulted in 2.3- and 2.2-
fold  decreases  in  cellular  GL-3  levels  when  measured  10  and 
14  days  postincubation,  respectively,  as  compared  to  1.4-  and 
1.5-fold reductions following incubation with rhα-Gal A alone 
(Supplementary Figure S2d); this effect was dependent on AT1001 
concentration [Figure 2b (red bars) and Table 1]. At a clinically 
achievable concentration of AT1001 (10 μmol/l, the approximate 
maximal plasma concentration in humans following oral admin-
istration of 150 mg AT1001),26 the magnitude of the decrease in 
cellular GL-3 levels that was seen 10 days after coincubation was 
nearly maximal [Figure 2b (red bars) and Table 1]. The EC50 value 
for decreasing GL-3 levels in C52S fibroblasts was approximately 
sixfold lower following AT1001 coincubation compared to incu-
bation with rhα-Gal A alone [0.12 ± 0.03 nmol/l (n = 5) versus 
0.7 ± 0.3 nmol/l (n = 5), respectively; P < 0.05 by t-test; Figure 2c 
(red lines)], indicating that AT1001 also increased the potency of 
rhα-Gal A-mediated GL-3 reduction. The effect of coincubation 
on both α-Gal A and GL-3 levels was dependent upon simulta-
neous addition of rhα-Gal A and AT1001 in the growth media 
(Supplementary Figure S3). In R301Q and L300P fibroblasts, rhα-
Gal A and AT1001 coincubation similarly resulted in decreases 
in cellular GL-3 levels (2.7- and 1.7-fold reductions, respectively) 
that were greater than those seen with rhα-Gal A alone (1.5- and 
1.2-fold reductions, respectively) (Table 1).
At1001 coadministration increases the circulating 
half-life of rhα-Gal A in rats and mice
To investigate the effects of increased rhα-Gal A stability in vivo, 
AT1001 was coadministered with rhα-Gal A in rats. Oral admin-
istration of AT1001 (3 mg/kg) 30 minutes before bolus tail vein 
injection of rhα-Gal A (10 mg/kg) (i.e., at AT1001 Tmax, to maxi-
mize the physical interaction between the two in the circulation), 
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Figure 2  At1001/recombinant human α-Gal A (rhα-Gal A) coincuba-
tion leads to greater α-Gal A levels and activity in Fabry fibroblasts. 
(a) Fabry fibroblasts expressing C52S α-Gal A were incubated with rhα-
Gal A (0.5 nmol/l) alone or in the presence of increasing concentrations 
of AT1001 for 5 hours. α-Gal A protein levels in cell lysates were mea-
sured by western blot 2 days later. The data shown are representative 
of four independent experiments (Table 1). (b) C52S Fabry fibroblasts 
were incubated with rhα-Gal A (0.5 nmol/l) alone or in the presence of 
increasing concentrations of AT1001 (0.1, 1, 10, 100, or 1,000 μmol/l) for 
5 hours. α-Galactosidase A (α-Gal A) activity (blue bars) in cell lysates was 
then measured 2 days later. The data points shown are the mean ± SEM of 
four wells tested in parallel from one representative of three independent 
experiments  (Table  1).  Globotriaosylceramide  (GL-3)  levels  (red  bars) 
were measured 10 days later. The data points represent mean ± SEM of 
three wells tested in parallel from one representative of three independent 
experiments (Table 1). The arrows indicate 10 μmol/l AT1001. (c) C52S 
Fabry fibroblasts were incubated with increasing concentrations of rhα-
Gal A alone or in the presence of 1 mmol/l AT1001 for 5 hours. α-Gal A 
activity (blue lines) and GL-3 levels (red lines) in cell lysates were measured 
2 and 10 days later, respectively. The data points shown are the mean ± 
SEM of four wells tested in parallel from one representative experiment. 
Similar effects of coincubation described in panels a and b were seen in 
R301Q and L300P fibroblasts (Table 1). *P < 0.05 compared to base-
line; #P < 0.05 compared to rhα-Gal A alone, as determined by one-way 
ANOVA with Bonferroni post-hoc analysis.720  www.moleculartherapy.org  vol. 20 no. 4 apr. 2012     
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resulted in an approximate 2.6-fold increase in the circulating 
half-life of the enzyme (Figure 3a, upper panel). In the absence 
of AT1001, rhα-Gal A activity declined rapidly, with a half-life of 
24 ± 0.5 minutes; AT1001 coadministration increased the half-life 
to 63 ± 4 minutes. Western blotting indicated that coadministra-
tion led to 2.5- and 1.5-fold higher rhα-Gal A protein levels in 
plasma 60 and 240 minutes postinjection, respectively (Figure 3a, 
lower panel). Similarly, studies conducted in GLA KO mice dem-
onstrated  that  oral  administration  of  AT1001  (3  or  10 mg/kg) 
30 minutes before injection of rhα-Gal A (1 mg/kg) also signifi-
cantly increased the circulating levels of recombinant enzyme. In 
the absence of AT1001, plasma α-Gal A levels were nearly unde-
tectable  240  minutes  postinjection.  In  contrast,  AT1001  coad-
ministration led to increases in α-Gal A activity 60-, 120-, and 
240-minutes postinjection that were up to 12-, 40-, and 90-fold 
greater, respectively, than those seen following administration of 
rhα-Gal A alone (Figure 3b, upper panel). Western blotting con-
firmed the higher plasma α-Gal A protein levels in GLA KO mice 
(Figure 3b, lower panel).
coadministration of At1001 increases tissue α-Gal A 
uptake and Gl-3 reduction in GLA Ko mice
Preliminary  studies  demonstrated  that  a  single  tail  vein  injec-
tion of rhα-Gal A dose-dependently increased α-Gal A activity 
and reduced GL-3 levels in the skin, heart, and kidney of GLA 
KO mice 7 days postadministration, with 3 mg/kg showing the 
greatest effects (Supplementary Figure S4). Three days postad-
ministration of 1 mg/kg rhα-Gal A, significant increases in α-Gal 
A activity were seen that were up to 2.0-, 8.5-, and 5.4-fold above 
baseline in skin, heart, and kidney, respectively [Figure 4a (red 
bars) and Table  2]. Importantly, oral administration of AT1001 
30 minutes before, and 2 hours after, rhα-Gal A injection resulted 
in even greater α-Gal A levels that were up to 2.7-, 4.1-, and 5.2-
fold higher, respectively, than those seen with rhα-Gal A alone 
[Figure 4a (blue bars) and Table 2]. In contrast, administration 
of a tenfold lower dose of rhα-Gal A (0.1 mg/kg) did not result 
in increased α-Gal A activity above baseline [Figure 4a (pink 
bars) and Table  2]; however, α-Gal A levels were significantly 
increased up to 1.6-, 2.5-, and 3.5-fold above baseline in skin, 
heart, and kidney, respectively, following coadministration with 
AT1001 [Figure 4a (green bars) and Table  2]. These effects on 
α-Gal A tissue levels were also seen 7 days after coadministration 
(Table 2). Notably, AT1001 coadministration with 1 mg/kg rhα-
Gal A resulted in significantly greater enzyme levels in heart and 
kidney compared to those seen following 3 mg/kg α-Gal A alone 
(Table 2).
Concomitant with the effects on α-Gal A tissue levels, AT1001 
coadministration also resulted in greater tissue GL-3 reduction in 
table 1  effect of rhα-Gal A and At1001 coincubation on cellular α-Gal A and Gl-3 levels in Fabry patient-derived fibroblasts
Fibroblast genotype rhα-Gal A (nmol/l) At1001 (μmol/l)
α-Gal A protein (increase relative 
to rhα-Gal A alone)
α-Gal A activity  
(nmol/mg/hour)
Gl-3 levels  
(% of control)
C52S (c.155 G>C) 0 0 nd 0 ± 1 100 ± 6
0.5 0 1 8 ± 3 67 ± 7*
0.5 0.1 nt 14 ± 6* 56 ± 8*
0.5 1.0 nt 20 ± 6* 44 ± 9*,**
0.5 10 4.4 ± 1.1*,** 20 ± 5* 40 ± 8*,**
0.5 100 4.7 ± 1.5*,** 22 ± 8*,** 37 ± 10*,**
0.5 1,000 5.6 ± 2.0*,** 25 ± 11*,** 39 ± 8*,**
R301Q (c.902 G>A) 0 0 nd 1 ± 1 100 ± 4
0.5 0 1* 7 ± 3 67 ± 10*
0.5 0.1 nt 8 ± 3 67 ± 9*
0.5 1.0 nt 14 ± 3* 51 ± 9*
0.5 10 4.8 ± 1.5*,** 14 ± 4* 39 ± 9*,**
0.5 100 5.0 ± 1.6*,** 22 ± 4*,** 38 ± 8*,**
0.5 1,000 4.7 ± 1.5*,** 23 ± 9*,** 36 ± 7*,**
L300P (c.899 T>C) 0 0 nd 0.4 ± 0.5 100 ± 4
0.5 0 1 6 ± 2 84 ± 8
0.5 0.1 nt 8 ± 3* 79 ± 9*
0.5 1.0 nt 14 ± 5*,** 67 ± 9*
0.5 10 4.1 ± 0.9* 16 ± 4*,** 62 ± 10*,**
0.5 100 4.5 ± 1.3*,** 18 ± 4*,** 58 ± 8*,**
0.5 1,000 4.2 ± 1.3*,** 18 ± 5*,** 60 ± 7*,**
Abbreviations: GL-3, globotriaosylceramide; nd, not detectable; nt, not tested; rhα-Gal A, recombinant human α-Gal A; α-Gal A, α-galactosidase A.
Three different male Fabry patient-derived fibroblast cell lines (with the indicated genotypes) were incubated with rhα-Gal A (0.5 nmol/l) alone or in the presence 
of increasing concentrations of AT1001 for 5 hours. α-Gal A protein levels and α-Gal A activity were measured in cell lysates 2 days later. Cellular GL-3 levels were 
measured 10 days later. Data represent the mean ± SEM of three or more independent experiments.
*P < 0.05 compared to baseline; **P < 0.05 compared to rhα-Gal A incubation alone; one-way ANOVA with Bonferroni post-hoc analysis.Molecular Therapy  vol. 20 no. 4 apr. 2012  721
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GLA KO mice. Seven days after a single administration of 1 mg/kg   
rhα-Gal A, skin, heart, and kidney GL-3 levels were reduced by 
69 ± 4%, 71 ± 3%, and 58 ± 5%, respectively [Figure 4b (red bars) 
and Table 2]. Oral administration of AT1001 (30, 100, or 300 mg/
kg) 30 minutes before, and 2 hours after, rhα-Gal A administration 
reduced GL-3 levels by 93 ± 2%, 94 ± 2%, and 93 ± 3%, respec-
tively [Figure 4b (blue bars) and Table 2]. Notably, coadministra-
tion of AT1001 with 1 mg/kg rhα-Gal A reduced tissue GL-3 levels 
more than administration of the higher dose of 3 mg/kg rhα-Gal A 
alone (Table 2). Importantly, administration of the lower dose of 
0.1 mg/kg rhα-Gal A reduced GL-3 levels approximately twofold 
in heart only [i.e., there was no significant effect on skin or kidney 
GL-3 levels; Figure 4b (pink bars) and Table 2]; however, GL-3 
was significantly reduced in all three tissues following coadmin-
istration of AT1001 with the low dose of rhα-Gal A [Figure 4b 
(green bars) and Table 2]. Similar effects of coadministration were 
seen with 0.3 mg/kg rhα-Gal A (Table  2). Furthermore, immu-
nohistochemistry demonstrated that coadministration results in 
greater GL-3 reduction in cardiac smooth muscle cells of blood 
vessel walls and in renal distal tubular epithelial cells in the GLA 
KO mice (Figure 4c).
Lastly, the effects of coadministration were investigated using 
a single administration of AT1001 at doses (3 and 10 mg/kg) that 
lead to plasma exposures in mice that are comparable to those 
seen  in  humans  following  oral  administration  of  150 mg  and 
450 mg, respectively.21,26 Again, administration of AT1001 30 min-
utes before rhα-Gal A (1 mg/kg) resulted in sustained circulating 
plasma levels of α-Gal A (Figure 3b), and up to 2.3-, 2.6-, and 2.5-
fold greater enzyme levels 1 day postadministration in skin, heart, 
and kidney, respectively, compared to those seen following rhα-Gal 
A administration alone (Figure 5a and Supplementary Table S1); 
greater α-Gal A levels were also seen 3 and 7 days postinjection 
(Supplementary Table S1). Importantly, coadministration also led 
to significantly greater reduction in tissue GL-3 levels compared 
to administration of rhα-Gal A alone, with ~4.0-, 2.5-, and 2.0-
fold greater reductions seen in skin, heart, and kidney, respectively 
(Figure 5b). Collectively, these data indicate that coadministration 
of AT1001 to GLA KO mice at doses that yield clinically achievable 
exposures can significantly increase α-Gal A activity and reduce 
GL-3 levels in disease-relevant tissues to a greater extent than seen 
following administration of rhα-Gal A alone.
dIscussIon
Regular infusion of rhα-Gal A is the primary treatment for Fabry 
disease,  and  is  associated  with  clinical  efficacy.  However,  rhα-
Gal A has some limitations, including instability at neutral pH,27 
a short-circulating half-life,5 and variable and inefficient uptake 
into some cell types and tissues.28–33 AT1001 is a PC that selec-
tively binds to endogenous α-Gal A, increasing physical stability, 
lysosomal trafficking, and activity in cultured cells14,16,17,20,34 and in 
Fabry disease-relevant tissues in vivo.18,19 Recently, PCs have been 
shown to increase the stability23,24,35,36 and to improve the cellular 
and tissue uptake of several exogenous recombinant enzymes that 
are used to treat LSDs, including rhα-Gal A.23,24,35,36
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Figure 3  At1001 increases the circulating half-life of recombinant human α-Gal A (rhα-Gal A). (a) Eight-week-old male Sprague-Dawley rats 
were administered either vehicle (water) or AT1001 (3 mg/kg) via oral gavage. Thirty minutes later, vehicle (saline) or rhα-Gal A (10 mg/kg) was 
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independent studies. Each time point represents the mean ± SEM of the activity measured from nine rats. Each lane on the western blot contains 
plasma from a single rat, and is representative of two rats in each group. (b) Twelve-week old male GLA knockout (KO) mice were administered either 
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Our studies indicate that the binding of AT1001 to rhα-Gal 
A significantly increases the physical stability of the enzyme in 
neutral pH buffer, as well as in human blood ex vivo. In addition, 
coincubation of rhα-Gal A with AT1001 results in greater α-Gal A 
uptake and activity in Fabry patient-derived fibroblasts. An ear-
lier study revealed similar findings in a cell-based assay.23 Several 
mechanisms could explain these effects of AT1001, including: (i) 
extracellular stabilization of rhα-Gal A, leading to higher con-
centrations of properly folded, functional enzyme that can bind 
to and be internalized by mannose 6-phosphate receptors on the 
cell surface, (ii) stabilization of rhα-Gal A in endocytic vesicles 
and other nonlysosomal compartments, leading to less intra-
cellular  degradation,  and/or  (iii)  stabilization  and  prolonged 
half-life of functional rhα-Gal A in lysosomes. As the effects of 
coincubation on cellular α-Gal A levels require the simultaneous 
presence of rhα-Gal A and AT1001 in the growth medium for 
only a few (3–5) hours, we speculate that the increased uptake 
results  from  extracellular  stabilization  of  the  properly  folded 
protein,  consistent  with  previously  proposed  mechanisms.23,24 
However, it is possible that dissociation of AT1001 from rhα-Gal 
A is sufficiently slow, such that the internalized enzyme remains 
stable subsequent to endocytosis and/or lysosomal delivery. To 
gain more insight into the mechanisms that mediate the effects 
of AT1001, future studies should directly measure the rate of 
AT1001 entry and exit from lysosomes, the binding affinities of 
rhα-Gal A for the mannose 6-phosphate receptors in the absence 
and presence of AT1001, and the dissociation rates of AT1001 
from rhα-Gal A at both neutral and lysosomal pH.
Similar to the stabilizing effects seen in vitro, AT1001 coad-
ministration to mice and rats also prolonged the circulating 
half-life of rhα-Gal A. Importantly, these effects were seen at 
doses that result in plasma concentrations of ~10 μmol/l and 
30 μmol/l, which are comparable to those achieved in humans 
following  oral  administration  of  150  and  450 mg  AT1001, 
respectively.21,26  Furthermore,  AT1001  coadministration  also 
resulted in up to threefold higher levels of α-Gal A activity in 
disease-relevant tissues of GLA KO mice that were sustained 
well above baseline for up to 7 days. We hypothesize that bind-
ing of AT1001 to rhα-Gal A may sufficiently increase the physi-
cal stability of the exogenous enzyme to minimize or prevent 
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Figure 4  coadministration of At1001 promotes greater α-galactosidase A (α-Gal A) uptake and globotriaosylceramide (Gl-3) reduction in 
tissues of GLA knockout (Ko) mice. Twelve-week-old male GLA KO mice were administered either vehicle (water) or AT1001 (30, 100, or 300 mg/kg)   
via oral gavage. Thirty minutes later, vehicle (saline) or recombinant human α-Gal A (rhα-Gal A) (0.1 or 1 mg/kg) was administered via bolus tail 
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thermally  and  neutral  pH-mediated  denaturation,  as  well  as 
proteolysis, in the blood. A longer circulating half-life may offer 
more chances for recognition by mannose 6-phosphate recep-
tors and uptake into disease-relevant cells/tissues. In addition, 
reduced asialoglycoprotein receptor-mediated clearance of rhα-
Gal A by the liver could contribute to the prolonged circulating 
half-life and higher tissue levels of exogenous enzyme.37 As ele-
vated levels of rhα-Gal A in target cells and tissues are desirable 
for the treatment of Fabry disease, with some cell types showing 
very poor uptake,5,28–33,38 AT1001 coadministration could have a 
significant impact on the overall efficacy of rhα-Gal A. To this 
end, AT1001 coadministration significantly improved uptake 
of rhα-Gal A into smooth muscle cells of cardiac blood vessels 
and distal tubular epithelial cells of the kidney. Future studies 
to more closely investigate the effects of AT1001 on rhα-Gal A 
uptake into different disease-relevant cell types are warranted.
Importantly, the combination of AT1001 and rhα-Gal A leads 
to a greater effect on the key substrate GL-3 in Fabry fibroblasts 
and in cells and tissues of GLA KO mice. In the cell-based stud-
ies, the greatest GL-3 reduction seen after coincubation followed 
an unexpectedly long time-course, requiring 10–14 days to mani-
fest. This may be due to relatively slow GL-3 turnover in these cells, 
particularly if the substrate is accumulated in nonlysosomal cel-
lular compartments and requires redistribution to lysosomes for 
hydrolysis.3,39 However, the possibility of prolonged binding and 
stabilization of rhα-Gal A by AT1001 in lysosomes cannot be ruled 
out. In our studies with GLA KO mice, tissue GL-3 levels were only 
assessed 7 days after coadministration; thus, studies to investigate 
the time course for GL-3 reduction in vivo are warranted.
It should be noted that the maximal effect of coincubation on 
GL-3 reduction in Fabry fibroblasts was seen with 0.5 nmol/l rhα-
Gal A, a concentration that is just below the observed EC50 value 
and that leads to only partial GL-3 reduction (≤50% of maximum). 
Importantly,  coincubation  with  AT1001  resulted  in  an  approxi-
mately  sixfold  leftward  shift  in  the  EC50  value,  indicating  that 
AT1001 actually increases the potency of α-Gal A. Indeed, AT1001 
coincubation with 0.5 nmol/l rhα-Gal A resulted in robust GL-3 
clearance that was similar to the maximum reductions seen follow-
ing incubation with higher concentrations of rhα-Gal A alone (i.e., 
5 nmol/l–50 nmol/l). An increased potency for GL-3 reduction was 
also observed in tissues of GLA KO mice following coadministra-
tion. This was most evident by the enhanced efficacy seen at the 
lower dose of rhα-Gal A (0.1 mg/kg), which had minimal effects on 
skin and kidney GL-3 levels when administered alone.
In humans, the maximum concentration of rhα-Gal A mea-
sured in plasma during infusion with 1 mg/kg agalsidase β is 
approximately 50 nmol/l.5,40 While our cell-based studies suggest 
that further stabilization of rhα-Gal A at this concentration may 
not have a significant added benefit, our in vivo studies clearly 
show improved GL-3 clearance at both therapeutic (1 mg/kg) 
and subtherapeutic (0.1 and 0.3 mg/kg) dose levels. It is possible 
that GL-3 reduction in cultured fibroblasts is particularly sensi-
tive to low concentrations of rhα-Gal A, whereas the potency 
for mediating GL-3 reduction in disease-relevant tissues in vivo 
is  lower.  Hence,  AT1001-mediated  increases  in  the  maximal 
concentration  and/or  duration  of  circulating  rhα-Gal  A  may 
be primarily responsible for the greater tissue uptake and GL-3 
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reduction seen in mice. Furthermore, the half-life of rhα-Gal 
A in human plasma after infusion is about 45 minutes,41 with 
mean plasma concentrations decreasing to ~0.5 nmol/l within 
9 hours postinfusion.5 Thus, there may be a period of several 
hours following infusion when AT1001 could have a substantial 
impact on the low circulating levels of rhα-Gal A levels due to 
binding and increased stability. Our data suggest that improved 
efficacy could be derived from the currently recommended dose 
and regimen of rhα-Gal A when coadministered with AT1001. 
In addition, the sustained plasma and tissue α-Gal A levels seen 
in the mice following coadministration suggest the potential for 
reduced  dose  and/or  administration  frequency  of  ERT  while 
maintaining the same level of efficacy.5,40 Recent shortages in 
Fabry ERT supplies underscore the importance of investigating 
this possibility.
Collectively, our data indicate that AT1001 increases the sta-
bility and total cellular and tissue levels of exogenous rhα-Gal 
A, translating to greater enzyme activity and substrate turnover 
in situ. In our cell-based studies, the effect of AT1001 coincu-
bation on rhα-Gal A uptake and GL-3 reduction was seen in 
cultured fibroblasts derived from different male Fabry patients. 
These cell lines harbor different GLA mutations, differ by the 
presence or absence of detectable endogenous α-Gal A activity, 
and show different increases of endogenous α-Gal A in the pres-
ence of AT1001,17 suggesting that the beneficial effects of rhα-Gal 
A and AT1001 coadministration may not depend on the specific 
GLA genotype. As such, AT1001 coadministration may provide 
an improved therapeutic strategy that is broadly applicable to a 
diverse population of Fabry patients. Based on these encouraging 
findings, phase 2 clinical investigations have been initiated.
MAterIAls And MetHods
Materials. Male Fabry patient-derived (C52S, c.155 G>C; R301Q, c.902 
G>A; L300P, c.899 T>C) and normal human fibroblast cell lines (CRL2076) 
were from sources described previously.17 All cell culture reagents were 
purchased from Invitrogen (Carlsbad, CA), except for characterized fetal 
bovine  serum,  which  was  purchased  from  HyClone  (Waltham,  MA). 
AT1001  (1-deoxygalactonojirimycin  hydrochloride;  migalastat  hydro-
chloride; GR181413A) was synthesized by Cambridge Major Laboratories 
(Germantown,  WI).  rhα-Gal  A  (agalsidase  β;  Fabrazyme)  was  pur-
chased from Genzyme. Rabbit antihuman α-Gal A polyclonal antibody, 
CR0020, for western blots in cells and tissues was provided by Shire HGT 
(Cambridge, MA). Rabbit antihuman cyclophilin A and antihuman actin 
polyclonal antibodies were purchased from Millipore (Billerica, MA) and 
Invitrogen,  respectively.  Mouse  antihuman  GL-3  monoclonal  antibody 
was purchased from Seikagaku (Tokyo, Japan). Horseradish peroxidase 
conjugated  goat  anti-rabbit  secondary  antibody  was  purchased  from 
ThermoPierce (Rockford, IL). GLA knockout (KO) mice were obtained 
from Dr Robert Desnick (Mt Sinai University, New York, NY). Wild-type 
C57BL/6 mice and Sprague-Dawley rats (carotid artery cannulated) were 
purchased from Taconic Farms (Germantown, NY). Animal husbandry 
and all experiments were conducted under Institutional Animal Care and 
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Figure 5  A single oral administration of At1001 at doses that yield clinically achievable exposures in humans increases the tissue levels of 
recombinant human α-Gal A (rhα-Gal A) and leads to greater globotriaosylceramide (Gl-3) reduction in GLA knockout (Ko) mice. Twelve-
week-old male GLA KO mice were given a single oral administration of vehicle (water) or AT1001 (3 or 10 mg/kg, which result in plasma Cmax values of 
~10 and 30 μmol/l that are roughly equivalent to the Cmax values seen in humans following administration of 150 and 450 mg AT1001, respectively) 
30 minutes before bolus tail vein injection of 1 mg/kg rhα-Gal A. Mice were killed 1 or 7 days later for measurement of tissue (a) α-galactosidase A 
(α-Gal A) and (b) GL-3 levels (see Materials and Methods). α-Gal A data were normalized relative to baseline levels; GL-3 data were normalized rela-
tive to baseline levels of untreated GLA KO (100%) and wild-type C57BL/6 mice (0%). The bars on each graph represent the mean ± SEM for 5 mice/
group. #P < 0.05, compared to rhα-Gal A administration alone, as determined by one-way ANOVA with Bonferroni post-hoc analysis.Molecular Therapy  vol. 20 no. 4 apr. 2012  725
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Use Committee approved protocols. All other reagents were purchased 
from Sigma Aldrich (St Louis, MO) unless noted otherwise.
Thermal stability assay. The stability of rhα-Gal A was assessed using a 
modified fluorescence thermostability assay25 on a Realplex Mastercycler 
qRT-PCR  system  (Eppendorf,  Hamburg,  Germany)  in  either  neutral 
pH buffer (25 mmol/l sodium phosphate, 150 mmol/l sodium chloride, 
pH 7.4) or acidic pH buffer (25 mmol/l sodium acetate, 150 mmol/l sodium 
chloride, pH 5.2). Briefly, rhα-Gal A (2.5 μg) was combined with SYPRO 
Orange and various concentrations of AT1001 in a final reaction volume of 
25 μl. A thermal gradient was applied to the plate at a rate of 1 °C/minute, 
during which time the fluorescence of SYPRO Orange was continuously 
monitored. The fluorescence intensity at each temperature was normalized 
to the maximum fluorescence after complete thermal denaturation. For 
time-dependent denaturation assays, reactions were incubated at 37 °C for 
up to 24 hours, with SYPRO Orange fluorescence intensity monitored at 
the indicated time points and normalized to the maximum fluorescence 
after complete thermal denaturation.
Enzyme inactivation assay in whole blood. rhα-Gal A (1 nmol/l) was 
incubated with 1 μmol/l AT1001 for 10 minutes on ice in human whole 
blood (Lampire, Pipersville, PA). Reactions were then transferred to 37 °C, 
with aliquots removed and diluted 500× (to ensure minimum inhibition of   
rhα-Gal  A  by  AT1001)  at  the  indicated  times  and  incubated  for  an 
additional  1  hour  at  37 °C  in  rhα-Gal  A  reaction  buffer  (3 mmol/l 
4-methylumbelliferyl-α-D-galactopyranoside, 0.1% Triton X-100, 0.1 mol/l 
citrate phosphate, pH 4.6). Reactions were stopped by the addition of an 
equal volume of 0.5 mol/l sodium carbonate (pH 10.5). Liberated 4-MU 
was measured on Victor3 plate reader (Perkin Elmer, Waltham, MA) at 
355 nmol/l excitation and 460 nmol/l emission, with fluorescence plotted 
as a function of time. Data were normalized to the activity at time zero.
Western blot analysis in Fabry patient fibroblasts. Fabry fibroblasts were 
seeded in a T-75 flask at a density of one million cells in growth medium 
(Dulbecco’s modified Eagle medium + 15% fetal bovine serum) and incu-
bated at 37 °C, 8% CO2 overnight. The cells were then incubated with 
rhα-Gal A (0.5 nmol/l) alone, AT1001 alone (1,000 μmol/l), or rhα-Gal A 
(0.5 nmol/l) and AT1001 (10, 100, or 1,000 μmol/l) for 5 hours. The cells 
were then washed three times with growth medium, and maintained in 
growth medium at 37 °C, 8% CO2 for 2 days. After, the cells were washed 
twice with Dulbecco’s phosphate-buffered saline and lysed (5 minutes in 
200 μl of 0.5% Triton X-100, 27 mmol/l citric acid monohydrate, 46 mmol/l 
phosphate buffer, pH 4.6). The protein concentration in the lysates was 
determined using a MicroBCA Protein Assay Kit (ThermoPierce) accord-
ing to the manufacturer’s instructions. Ten to fifteen microgram of total 
protein were loaded per lane and blotted as described previously,17 except 
that the anti-α-Gal A primary antibody, CR0020, was diluted 1:2,000, and 
the anti-cyclophilin A loading control antibody was diluted 1:4,000. The 
net intensity of the α-Gal A band was normalized to the net intensity of 
the cyclophilin A band in each lane. The ratio of α-Gal A to cyclophilin 
A was compared across lanes to calculate the relative increase in α-Gal A 
protein after coincubation.
α-Gal A activity assay in Fabry patient fibroblasts. Fabry patient fibro-
blasts were seeded in sterile, clear-bottom, 96-well black plates (Corning 
Costar, Corning, NY) at 10,000 cells/well, and incubated at 37 °C, 8% CO2 for  
1–2 hours. The cells were then incubated with rhα-Gal A (0.5 nmol/l) alone, 
or rhα-Gal A (0.5 nmol/l) and AT1001 (0.1, 1, 10, 100, or 1,000 μmol/l) for 
5 hours. The cells were washed three times with growth medium, and then 
maintained in growth medium at 37 °C, 8% CO2 for 2 days. After, the cells 
were washed twice with Dulbecco’s phosphate-buffered saline, and lysed 
in 35 μl 0.2% Triton X-100, 27 mmol/l citric acid monohydrate, 46 mmol/l 
phosphate buffer, pH 4.6, for 5 minutes. Enzyme activity was measured as 
described previously, and is expressed as the nanomoles of 4-MU liberated 
per mg protein/hour (nmol/mg protein/hour).17
Immunofluorescence detection of GL-3 in Fabry patient fibroblasts. Fabry 
patient fibroblasts were seeded at 10,000 cells/well in glass-bottom 96-well 
black plates (Thermo Scientific Nunc, Pittsburgh, PA) that were coated with 
10 μg/ml of human plasma fibronectin (Invitrogen) for 1 hour at 37 °C. The 
cells were incubated at 37 ºC, 8% CO2 for 1–2 hours to promote attachment, 
then incubated with rhα-Gal A in the absence or presence of AT1001, fol-
lowed by washing as described for the α-Gal A activity assay. The cells were 
maintained in growth medium at 37 °C, 8% CO2 for 10 days. After, the cells 
were washed twice with Dulbecco’s phosphate-buffered saline, and GL-3 
analysis by immunostaining was performed as previously described.17 For 
data analysis, the GL-3 fluorescence intensity was divided by the actin fluo-
rescence intensity to obtain the GL-3 to actin fluorescence ratio (referred 
to as the “GL-3 level” in the cell-based experiments). Fabry fibroblast GL-3 
levels were normalized to the percentage of GL-3 levels in normal untreated 
fibroblasts (defined as 0%) and untreated Fabry fibroblasts (of the same cell 
line) measured in parallel (defined as 100%).
AT1001/rhα-Gal A coadministration studies in rats. Eight-week-old male 
Sprague-Dawley rats were administered either vehicle (water) or AT1001 
(3 mg/kg) via oral gavage. Thirty minutes later, vehicle (saline) or rhα-Gal A 
(10 mg/kg) was administered via bolus tail vein injection. Whole blood was 
collected into lithium heparin tubes from the carotid artery cannula at the 
indicated time points. Plasma was collected by centrifuging blood at 2,700g 
for 10 minutes at 4 °C, and was used for measurement of α-Gal A activity as 
described below.
Coadministration studies in GLA KO mice. In the studies shown in Figure 4 
and Table 2, 12-week old male GLA KO mice were administered rhα-Gal 
A (0.1, 0.3, 1, or 3 mg/kg) via bolus tail vein injection. Mice were coadmin-
istered vehicle (water) or AT1001 (30, 100, or 300 mg/kg) via oral gavage, 
30 minutes before, and 2 hours after, rhα-Gal A administration. Mice were 
euthanized 3 or 7 days after rhα-Gal A administration as indicated. In the 
studies shown in Figure 5, 12-week old male GLA KO mice were adminis-
tered rhα-Gal A (1 mg/kg) via bolus tail vein injection. Mice were coadmin-
istered vehicle (water) or AT1001 (3 or 10 mg/kg, which result in plasma Cmax 
values of ~10 μmol/l and 30 μmol/l, respectively, that are roughly equivalent 
to the Cmax values seen in humans following oral administration of 150 and 
450 mg AT1001, respectively) via oral gavage, 30 minutes before rhα-Gal A 
administration. Mice were killed 1 or 7 days following rhα-Gal A adminis-
tration. Heart, kidney, and skin (shaved and removed from the lower ventral 
side of the neck) were quickly removed, rinsed in cold phosphate-buffered 
saline, blotted dry, and stored on dry ice. Samples of heart and kidney were 
stored in 4% paraformaldehyde for immunohistochemical analysis. Tissue 
α-Gal A activity, protein, and GL-3 levels were assessed using methodolo-
gies described previously.19 Baseline α-Gal A activities in C57BL/6 mouse 
skin, heart, and kidney were 9 ± 0.5, 2.5 ± 0.2, and 8 ± 0.4 nmol/mg protein/
hour, respectively; baseline activities in GLA KO mouse tissues were 0.5 ± 
0.04, 0.1 ± 0.04, and 0.3 ± 0.02, nmol/mg protein/hour, respectively. Baseline 
GL-3 levels in C57BL/6 mouse skin, heart, and kidney were 5 ± 0.6, 8.4 ± 1, 
and 74 ± 7 μg/g tissue weight, respectively; baseline levels in GLA KO mice 
were 1,500 ± 123, 387 ± 22, and 503 ± 24 μg/g tissue, respectively. For plasma 
α-Gal A activity measurements, samples were diluted 50-fold before assay; 
~10 μg of total protein was used for western blotting.
Data analysis. Determinations of statistical significance were conducted 
using Excel 2003 (Microsoft, Redmond, WA) or GraphPad Prism, ver-
sion 5 (San Diego, CA) as defined in the figure and table legends. Linear 
trends for dose-dependence were calculated using a one-way ANOVA in 
GraphPad Prism. The half-life (t1/2) of rhα-Gal A in plasma was calculated 
using a nonlinear one-phase exponential decay curve fitting function in 
GraphPad Prism.
suPPleMentArY MAterIAl
Figure S1.  Fabry fibroblast cell lines show high baseline GL-3 levels 
that are decreased after incubation with rhα-Gal A.726  www.moleculartherapy.org  vol. 20 no. 4 apr. 2012     
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Figure S2.  Concentration-  and  time-dependence  of  rhα-Gal 
A-mediated effects on Fabry fibroblasts.
Figure S3.  The effects of rhα-Gal A and AT1001 in Fabry fibroblasts 
(C52S) are dependent on the timing of coincubation.
Figure S4.  rhα-Gal A dose-dependently increases in α-Gal A activity 
and decreases in GL-3 levels in GLA KO mice.
Table S1.  Coadministration of AT1001 at doses that yield clinically 
achievable exposures in humans increases the tissue levels of rhα-Gal 
A in GLA KO mice.
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